bariatric surgery vs semaglutide Unique and Shared Effects of and GLP-1RA Ozempic vs. Bariatric Surgery -

Description

Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations

The researchers found that GLP-1 receptor agonist initiation was associated with a reduced risk for disorders related to alcohol use, cannabis use, cocaine use, nicotine use, opioid use, and other SUDs compared with initiation of SGLT-2 inhibitors (hazard ratios, 0.82, 0.86, 0.80, 0.80, 0.75, and 0.87, respectively) and with a reduced risk for the composite outcome of all incident SUDs (hazard ratio, 0.86)

This might include more frequent blood glucose monitoring (fingerstick or continuous glucose monitoring) and temporary use of short-acting insulin or other antihyperglycemic agents according to their healthcare provider's recommendations

semaglutide Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity | Description: Drug dosage: ADMET properties: Approvals: FDA Adverse Event Reporting System (Female) FDA Adverse Event Reporting System (Male) FDA Adverse Event Reporting System (Geriatric) FDA Adverse Event Reporting System (Pediatric) None Pharmacologic Action: Drug Use | Suggest Off label Use Form| |View source of the data| Veterinary Drug Use None Veterinary products None Acid dissociation constants calculated using MoKa v3.0.0 Orange Book patent data (new drug applications) Orange Book exclusivity data (new drug applications) Bioactivity Summary: External reference: Pharmaceutical products:

When integrated into a standardized research protocol, Semaglutide 12.5mg provides a consistent baseline for observing physiological changes, enzymatic interactions, and gene expression profiles